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ANNUAL SCIENTIFIC
"™HE CAMA PROGRAM COMMITTEE

has put together an outstanding
scientific meeting for Seattle.
Some of the outstanding authorities have
been included to present the "Neuropsych
Issues in Civil Aviation Medicine." For more
information about the meeting, see the
President's column (page 2) and the meeting
agenda (page 6).
Seattle Tours
With the outstanding program comes
a chance to enjoy the Northwest. Blue water, not yellow brick, surrounds the Emerald City of Seattle. Cupped between the
jagged Olympic Mountains to the west
and the volcanic peaks of the Cascade
Range to the east the city sits on a narrow strip of land between Puget Sound
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MEETING HIGHLIGHTS
and 18-mile-long Lake Washington.
Just north of downtown, these bodies are united by a system of locks
and a ship canal feeding into Lake
Union, which bisects the city. Frequent
rains and mist keep the surrounding
cleaner and greener than most other cities of similar size.
While many museum and attractions
are available for visits, the following
have been scheduled for our visit. On
Thursday afternoon, we will visit the
Seattle Art Museum, which houses a renowned collection of Asian, African,
and Northwest Coast Indian art. The
collection also contains European
paintings and decorative, as well as
20 th -century American, ancient
Continued on page 19
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THE ENIGMA OF HUMAN BRAIN AGING
When will the diagnosis, prevention, and pretreatment of senility, Alzheimer's,
dementia, and mania be possible? Many approaches to the diagnosis and prevention
of AD are encouraging, and there surely will be a better story tomorrow!
BY JAMES R. ALMAND, M.D.
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s WE ALL LOOK AHEAD to "after age 60" for
the airline captain and to our patient
population, as well as our own "silvering"
population, one eventually drifts off in thought
to the scourge of the elderly, the Big A
(Alzheimer's disease, AD) and to where we all
could wander.
Alzheimer's is a challenging complex disorder that yet eludes our science in diagnosing
the early stage of developing Alzheimer's disease and certainly in its treatment. Much, however, is evolving in Alzheimer recognition and
therapy.

The progression of AD is an unrelenting
evolution of decline in a person's activities of
daily living, behavior, and cognition. Inclusion criteria for the diagnosis of AD (established by the Alzheimer's Disease Association)
now provides a high degree of diagnostic
accuracy for detection of the disease (Rasmussen,D, et al., Alzheimer's Disease Association Discord 1996;10:180-8). Memory
loss is usually the first noted symptom. Clinical evaluation of the patient at risk should
include a comprehensive physical examination, to include neurological studies and
Continued on page 8
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A CENTURY OF PROGRESS IN AVIATION MEDICINE

THE
PRESIDENT'S THOUGHTS

After nearly 100 years of formulating medical standards for
pilots, perhaps the greatest change has been in the interpretation
and implementation of the standards, rather than in the nature
or language
of
the standards.
o
o
J
Annual Meeting
JGUST IS HERE and the annual
scientific meeting in Seattle
is just two months away. I
hope you have already made plans to
attend this year and have taken or will
take advantage of the early registration pricing.
The extras this year include the
Seattle Art Museum, a Boeing fabrication plant tour, the Seattle
Space Needle, and the Museum of
Flight. These wonderful attractions
combine with the premier scientific
presentations being offered will
provide an enjoyable, interesting,
and educational experience for yet
another CAMA year.
The planners and CAMA Executive are hopeful that the trend
of the last three or four years, where
negative comments were sparse to
non-existent, is continued with this
year's program.
The final agenda is somewhat
different from the version you received with your notice of the annual meeting. There was some lastminute tweaking to accommodate
all the activities we are providing.
Also, the Boeing plant visit had to
be scheduled for Friday morning
instead of Friday afternoon due to the
traffic situation in the Seattle area.
This year the scientific program
has been accredited by the American Academy of Family Physicians
for 17.25 hours of category I prescribed credit.

A

100 Years of Progress

Another topic that I would like
to address in this issue is that of
aviation medicine and its progress
over the last 100 years. This follows
on the theme I mentioned in my
online President's Comments last
month regarding the transitions in
the world of powered flight over the
last century.
The current aviation medical
standards are still anchored, to
some degree, to the early days of
flight. There has been, however, a
major move towards modernization. Each medical case that is identified as not meeting a given medical standard is looked at individually and a determination made in
light of risk factors, current condition, and prognosis. In a number
of cases, the pilot is found to be
clearly outside the limits of a particular medical standard but is
given the "authority" to continue
flying, usually with the submission
of more frequent follow-up reports.
This approach is considerably
different and much more pilotfriendly then simply saying no and
issuing a denial.
Canada, Britain, and the US are
some of the countries that take this
approach most often. The other
countries tend to adhere more
strictly to the ICAO-recommended
practices. The JAA countries have
reached a compromise on the medical standards that seem to be some-

BY ROBIN E. DODGE, MD

what more restrictive than the
North American philosophy. Although there is need for considerable more epidemiological study, I
find it interesting to note that those
cases offered special authority do
not seem to be the cause of more
medically related aircraft accidents
than the "normal" cases.
No matter how it is viewed, the
number of medically caused aircraft
accidents is still extremely small.
Thus, I find myself asking the question— "If we give special authority to an increasing number of cases
and the medical causes of accidents
remains low, do the standards, as
written, really have value?"
In addition to the above question, I have suggested since the
mid-1980s that, with the medical
knowledge we now have, the experiences we have accumulated with
the special issuance procedures, and
the advances in computing power,
it is feasible to develop a medical
standard matrix where the outer
parameter of the matrix is the validity period. Then, within that
limit, a pilot's individual validity is
determined by a given condition,
risk factors, and recommended follow-up requirements for specific
diseases.
Continued
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PROGRESS from page 2
On the other hand, when one looks
at the absolute number of pilots ever
given a truly final denial and it is realized just how small that number is
(roughly one-half of one percent), I
guess it is a fair question to ask— Is
the effort of developing an entirely new
system truly worth it?
Cardiovascular and neuropsychiatric conditions account for the largest
number of pilot denials. It is also
within these areas that the majority of
effort is concentrated on bestowing
special authorizations.
The result is that after nearly a hundred years of formulating medical
standards for pilots, perhaps the greatest change has been in the interpretation/implementation of the standards,
rather than in the nature or language
of the standards. Nearly 99.5% of all
applications for medical certifications
are granted in the US. I believe that
this number, by itself, says much about
the FAA's attempt to be fair to pilots.
For those who oppose the standards
altogether or complain that the FAA
does not care about pilots, I would say
they are hard pressed, in the face of
this statistic, to objectively carry their
point forward. Further, having experienced the aviation medical issue
from all perspectives— a pilot, an
AME, and a regulator— I am realistically aware that all three parties need
to work together to achieve harmony.
Have a safe and enjoyable Labor
Day weekend.
I look forward to seeing and meeting each of you in Seattle.

FP

VISIT CAMA's WEB SITE

(PEARLS, SQUIRRELS, & ZEBRAS)
• In Migraines, weather (low humidity
and cold temperatures) occurs as a trigger for classic migraines.
• Cervicogenic (now migraine) headaches, in occipito-frontal distribution,
can be related to upper-neck disability. The resultant trigemino vascular
system pain can be r e m i t t e d by
lidocaine blockage of C2 and C3 nerve
root input.
• Epidemiologic studies suggest that
statin therapy reduces the incidence of
Alzheimer's disease.
• Without data no opinion is of value.
• Evidence-based medicine is a wonderful thing. It seems as though one
takes the evidence one likes and uses
it, and ignores the rest.
• Agrifuel research from Purdue is
now shown to fuel tractors, buses, and
cars — all from soybeans. (Didn't
Hitler try this?)
• White coat hypertension (or "reactive BP elevation") is related to increased cardiovascular risk and can be
additive to the metabolic syndrome.
• Vulnerable coronary artery plaques
(thin fibrous cap and large lipid core)
can be identified, non-invasively,
through high-resolution MRI, remodeling, and restenosis after angioplasty
therapy can be followed.
• Random urine micro albumin, a
strong indicator of early diabetic and
hypertensive renal disease, is also a
strong predictor of death in one year
following acute myocardial infarction.
• In an early post MI patient, the albumin creatinine ratio is a reliable predictor of coronary mortality risk in
both diabetic and non-diabetic
patients.

WWW.CIVILAVMED.COMJ

Continued on page 15
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THE LATEST ON LAS IK
NEW LASER TECHNOLOGY MAY MEAN BETTER VISION FOR PILOTS
BY INGRID ZIMMER-GALLER, M.D.*

Jk

BOUT HALF OF ALL pilots in the

L^^ United States need some form
M »of vision correction, such as contact lenses or glasses, to meet medical
certification standards. But now pilots
with imperfect vision who want to fly
without corrective lenses have more options than ever, thanks to recently approved advances in laser corrective eye
surgery.
Since the Food and Drug Administration (FDA) first approved laser corrective eye surgery in 1995, more than
10 million people, including more than
11,000 pilots, in the United States have
undergone the surgery with the goal of
seeing better. And with the recent FDA
approval of a wavefront-guided system
for customized refractive surgery, pilots
can hope for even better outcomes.
Before getting into the new technology, let's first review the basics about laser corrective eye surgery, also called refractive surgery. Remember that a third
class medical certificate requires at least
20/40 vision in each eye for distant vision and for reading. A first- or second
class medical certificate requires 20/20
vision in each eye at distance and 20/40
in each eye for reading and intermediate distances of 32 inches. A pilot who
has had refractive surgery and meets the
FAA vision requirements no longer
needs the limitation requiring corrective
lenses on his or her medical certificate.
In most instances, older pilots still need
glasses to meet the near- and intermediate-distance vision requirements.
LASIK surgery
The most commonly performed type
of corrective eye surgery is LASIK, or
laser insitu keratomileusis. This procedure involves the use of an excimer laser—a laser that uses a combination of
argon and fluorine gases to produce a

specific wavelength of light—to permanently alter the shape of the clear front
covering of the eye, the cornea. The laser ablates, or vaporizes, part of the cornea, changing its shape and the refractive, or focusing, power of the eye.
LASIK may be used to correct myopia
(nearsightedness), hyperopia (farsightedness), astigmatism (irregularly shaped
cornea), or a combination of these (for
example, myopia with astigmatism).
Presbyopia is the normal loss of the ability to see clearly at close distances that
begins after age 40 and is most commonly corrected with reading glasses or
bifocals. Presently, LASIK cannot correct both distance vision and presbyopia in the same eye, although this is being investigated in clinical trials. In other
words, a patient who already needs reading correction can have LASIK to improve distance vision, but usually this
does not eliminate the need for reading
glasses.
Vision results today are quite good
with laser refractive surgery, and for the
majority of LASIK patients the surgery
improves vision. Results tend to be best
for patients with mild or moderate myopia. The vast majority of patients achieve
at least 20/40 vision and many reach 20/
20 vision. Most patients are very happy
with their surgical outcome. However,
LASIK still cannot provide perfect vision for every patient and as many as 10
percent of patients have some visual
problems or side effects after surgery.
This also means that even after surgery
some pilots require correction with
glasses or contact lenses to meet the vision requirements for their class of medical certificate.
Only a very small percentage of
patients permanently lose vision after laser corrective surgery. On the other

* Reprinted from the August 2003 issue oftheAQPA Pilot; with permission of the
Aircraft Owners and Pilots Association and Dr. Zimmer-Galler.

hand, a refractive surgery patient may
end up with 20/20 vision and still be
unhappy with the way he sees. Common complaints after LASIK surgery
include annoying glare from lights, halos around lights at night, and poor vision in dim lighting conditions. Such
visual aberrations after LASIK can cause
problems for the pilot in certain aviation environments, such as when flying
at night or in marginal VFR or IFR conditions, even though his vision may
measure a perfect 20/20 in the doctor's
office. Usually these visual complaints
improve within several months after
surgery, but occasionally they are significant enough to interfere with normal
activities. As an example, a recent highly
publicized case involved a commercial
airline pilot who obtained 20/15 vision
after LASIK surgery but had to end his
flying career because of disabling nightvision difficulties.
Wavefront technology
LASIK is not entirely risk-free, but
newly approved technologies may further decrease the likelihood of complications. One of the latest developments
in refractive surgery is wavefront technology. A wavefront-guided LASIK system allows the corneal laser ablation (vaporization and shaping) to be customized for each patient, possibly leading
to better individual vision outcomes.
But what's a wavefront anyway? A
perfect wavefront emanates from a light
source with a flat surface. When performing wavefront analysis of the eye, a
light source (the wavefront) passes
through the layers of the eye (tear film,
cornea, natural lens, and fluids in the
eye) to the retina in the back of the eye.
Irregularities in the wavefront are caused
by each of the components of the eye as
the light rays pass through it. The nowdistorted wavefront is measured as it
again emerges from the eye. A wavefront
sensor maps out the aberration or distortion profile of the entire eye, providing a fingerprint pattern specific to each
individual eye. Even subtle distortions
and imperfections are measured.
Continued —>

/Z/G//7PHYSICIAN
The excimer laser is then programmed to perform a customized ablation of the cornea based on the information received from the wavefront sensor. The cornea is thereby reshaped very
precisely to eliminate most aberrations
of the eye, theoretically resulting in perfect vision.
In conventional LASIK, corneal topography is used to determine the laser
ablation profile. Corneal topography
provides information about the curvature of the cornea but does not map out
distortions caused by other parts of the
eye through which light must pass.
Wavefront- guided refractive surgery
provides a new level of detail and accuracy not previously possible. Surgeons
are now able to treat a much broader
group of patients, improving not only
the level of vision but also reducing the
side effects. By correcting for all aberrations in an eye, wavefront technology
has the potential to allow patients to
achieve "super normal" vision, or vision
that is better than 20/20. Not only are a
high percentage of patients reaching 20/
20 vision, but with the new technology
many achieve levels of vision between
20/15 and 20/10. Perhaps more important, conventional LASIK surgery frequently causes a type of aberration that
is responsible for the night-vision problems that may occur after corrective laser surgery. Wavefrontguided LASIK has
the ability to correct not only natural
optical aberrations of the eye but also
the aberrations routinely induced by laser surgery. As a result, the incidence of
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night-vision difficulties after laser surgery should be reduced. Patients who
have had conventional LASIK in the
past and who are experiencing nightvision problems or visual symptoms may
benefit from retreatment with
wavefront- guided LASIK. Wavefront
technology also may allow refractive
surgery in some patients who are considered poor candidates for the procedure with conventional techniques.
Interestingly, wavefront technology
has been used in astronomy for many
years as a type of adaptive optics to remove the blurring effects of turbulence
in the atmosphere on telescopic images
of the heavens. This has allowed groundbased telescopes to achieve significant
improvements in resolution.
The FAA has approved refractive surgery for all classes of medical certification. After surgery, once your eye doctor has verified that healing is complete,
vision is stable, and there are no significant side effects or complications, you
may resume flying. Typically this occurs
within four weeks after surgery. The
FAA requests that your eye doctor send
a summary document to the Medical
Certification Division in Oklahoma.
Monovision surgery
Another relatively new option for pilots is monovision correction with refractive surgery. This refers to correction of
one eye for distance vision while the other
eye is corrected for reading vision. Therefore, each eye separately does not meet
both the near and distance vision requirements. The new FAA policy requires that

Vision Questions?
AOPA's medical certification specialists communicate with the FAA on an
almost daily basis to provide the most current information to members about
pilot medical certification. In addition, the Web site (www.aopa.org), includes
an entire medical area that contains valuable information about many of the
most common medical issues affecting pilots. Vision questions are among the
most frequently asked, and the Web site has several subject reports dealing
with FAA certification policy. The index for all medical subject reports can be
found online at:
www.aopa.org/members/files/ medical/hotsheet.html/medical
If you have questions about any medical certification issue that isn't answered on the Web site, call the medical certification specialists at 800/8722672.
—Gary Crump, AOPA's director of medical certification

pilots who opt for monovision refractive
surgery use glasses to meet the near and
far vision requirements while flying for six
months after surgery.
When not flying, you should not
wear corrective lenses to allow optimal
adaptation to the monovision state. After six months, you may apply for a
waiver with a medical flight test. Not
everyone is comfortable with monovision correction, and it is strongly encouraged that you undergo a severalweek trial period using monovision contact lenses before undergoing a permanent surgical procedure. Also, keep in
mind that while vision with only one
eye has been demonstrated to be safe in
the aviation environment, the overall
quality of vision is still better with two
eyes (binocular vision) than with one
eye, or monovision.
The FAA is currently considering
other types of vision correction for pilots, but presently does not approve flying with monovision contact lens correction. Similarly, the FAA does not at
this time approve bifocal contact lenses
for use while flying.
Advances in technology are revolutionizing vision correction surgery and
pilots have an ever-greater range of options for vision correction. Most LASIK
patients have good results and are able
to meet FAA vision certification requirements. However, no surgical procedure,
including wavefront-guided refractive
surgery, is entirely risk-free. When considering laser eye surgery, make certain
you discuss all the risks with your eye
surgeon, including the small possibility
of vision loss that may end an aviation
career. Refractive surgery has come a
long way, but there is still much work
to be done to achieve perfect vision in
every patient every time.

FP
Dr. Ingrid Zimmer-Galler, CAMA and
AOPA member, is a vitreoretinal surgeon
at Johns Hopkins' Wilmer Eye Institute. She
is also a commercial pilot and CFI with
instrument and seaplane ratings. She has
more than 1,600 hours and owns a
Beechcraft Bonanza and Piper Cub.
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THE CIVIL AVIATION MEDICAL ASSOCIATION
ANNUAL SCIENTIFIC MEETING AGENDA
October 8-12, 2003
Seattle Marriott Sea-Tac Airport
3201 S. 176th Street
Seattle, Washington 98188
Phone: (206) 241-2000
THEME: NEUROPSYCH ISSUES IN CIVIL AVIATION MEDICINE
WEDNESDAY, OCTOBER 8, 2003
4:30 p.m. - 8:30 p.m.

Registration

2:00 p.m. - 6:00 p.m.

Board of Trustees Meeting

General Session
1:00 p.m.

Virgil Wooten, M.D.
1:50 p.m.

THURSDAY, OCTOBER 9, 2003
6:45 a.m. - 7:45 a.m.

Breakfast

7:0 0 a.m. - 7:45 a.m.

Registration

2:20 p.m.

7:50 a.m.

Invocation: DeWayne E. Caviness, M.D.

8:00 a.m.

Administrative Announcements: James L.
Harris, M.Ed.

8:10 a.m.
8:15 a.m.
8:15 a.m.

9:15 a.m.

FRIDAY, OCTOBER 10, 2003
6:45 a.m.- 7:45 a.m. Breakfast
Buses will depart for Boeing Aircraft tour

11:00 a.m.

Lunch at Boeing

Opening Remarks: Robin E. Dodge, M.D.

12:00 p.m.

Buses will return to hotel

General Session Moderator: Robin E.
Dodge, M.D.

1:00 p.m.

General Session

Neuropsych Issues in Aviation Accidents.

1:00 p.m.

Moderator: H. Stacy Vereen, M.D.

Mitch Garber, M.D.

Discussion of ADHD, Diagnosis, Missed
Diagnosis, Treatment

Fatigue in the Cockpit

Gary Kay, Ph.D.
1:50 a.m.

Break

10:20 a.m.

Discussion of Fatigue by an ATP Pilot From
a Pilot's Perspective

2:50 p.m.

Captain Bruce Forbes

3:40 p.m.

Lunch

ASHRAE/FAA Multiple Factors Research
Dave Space, Ph.D., Boeing Aircraft

Chemical Dependency: How to Handle It
Once a Diagnosis is Made
Steven I. Altchuler, M.D.

FAA Perspective of ADHD
Bart Pakull, M.D.

10:05 a.m.

12:05 p.m.

Tour: Buses will depart from hotel for Seattle
Art Museum and dinner at the Space Needle

8:00 a.m.

Virgil Wooten, M.D.

11:00 a.m.

Aerospace Medicine, Historical Perspective
Clayton Cowl, M.D.

3:30 p.m.
Welcome: Robin E. Dodge, M.D., CAMA
President

In-Flight Medicine, Airline Experience
Susan Northrup, M.D.

General Session
7:45 a.m.

Sleep Disorders

Break 3:50 p.m.Cognitive Aspects of
Medication Use
Gary Kay, Ph.D.

4:40 p.m.

SSRI/Other Medications Update, Status of
Certification with Their Use
Warren Silberman, D.O.

Continued
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5:40 p.m.

Accidents Relating to Neuropsych Issues

1:30 p.m.

Moderator: Gordon Ritter, D.O.

Alex Wolbrink, M.D.
6:40 p.m.

1:30 p.m.

Adjourn

Breakfast

2:20 p.m.

General Session Chattahoochee - AB
7:45 a.m.

General Session

8:45 a.m.

SSRI Use in Pilots: Canadian Perspective
Marvin Lang, M.D.

3:00 p.m.

Moderator: Christopher Taylor, M.D.
7:45 a.m.

Time/Duty Requirement and Planning From
an Airline Perspective
Captain Thomas Bettes

SATURDAY, OCTOBER 11, 2003
6:45 a.m. - 7:45 a.m.

General Session

SSRI Use in Pilots: Australian Perspective
Graeme McLaren, M.D.

Medical Programs

3:40 p.m.

Break

Fredrick E. Tilton, M.D

4:35 p.m.

SSRI - ALPA Perspective

Panel Discussion: Neuropsych
Moderator: John Hastings, M.D.
Members: Stephen Goodman, M.D., Bart
Pakull, M.D., Gary Kay, Ph.D., Alex
Wolbrink, M.D.

Don Hudson, M.D.
5:10 p.m.

Panel: Documentation/Certification
Handling Problem Cases
Moderator: James R. Almand, M.D.

10:15 a.m.

Break

10:15 a.m.

Buses depart for Museum of Flight tour

12:15 p.m.

Buses depart for hotel

Members: Gary Kay, M.D., Bart Pakull,
M.D., Earl F. Beard, M.D., Don Hudson,
M.D., John D. Hastings, M.D., Robert A.
Stein, M.D., Fredrick E. Tilton, M.D.

12:30 p.m.

Lunch

Adjourn
Dinner: Honors Night
Awards Speaker: John Miller

Make your
reservations SOON!
CAMA Headquarters:
FAX (405) 848-1053
Phone (405)840-0199

CONTINUING MEDICAL EDUCATION

This activity has been reviewed and is acceptable for up to 17.25 prescribed credit hours by
the American Academy of Family Physicians.

PROGRAM OBJECTIVES
To understand and apply the changes in
aviation medicine to the individual's private
practice.
* To assess specific clinical conditions/
disciplines (neurology, psychiatry) with
respect to aviation medicine.
* To correctly utilize the federal aviation
medical standards with the specific conditions
discussed.
* To comprehend the FAA medical program
initiatives.
* To understand and be able to work with the
aeromedical certification system.
* To comprehend the legal aspects of being an
AME today.

FLIGHTPHYSICIAN

BIG A from page 1
laboratory evaluation (to rule out metabolic cause). Most common risk factors
are age and family history, with females
being more affected. As the patient ages,
prevalence of AD doubles each five years
above the age of 60, where it reaches
30% to 50% by age 85.
The number of octogenarians in the
United States today is four million. By
2030, there will be eight million, by
2040, there will be twelve million, and
by 2050, this number will top twenty
million.
Authorities liken AD today to the
status of cardiovascular disease years ago.
The prediction is for greater understanding and therapy for AD similar to the
recent therapeutic evolution of vascular disease.
A presymptomatic phase of AD can
occur silently in patients aged 20-30.
Slow progression to mild cognitive impairment follows at age 50-60 and to
fully developed AD at about age 70, with
marked brain changes of amyloid plaque
and neurofibrillary tangles. Factors involved in this progression of AD include
genetics, inflammation, environment,
and life style. The successful definition
of who will progress to AD is still not
possible. Special testing for phosphorylated TAU protein meets many criteria
for accurate ante mortem diagnosis of
AD (ARAI, H. Ann Neural, 2001).
The human brain has 100 billion
neurons. Circuitry differences in various species may explain subtle capacities in languages and even in diseases of
the brain (Am J Phys Anthropol, 2001).
The risk of AD is reported to be increased in people with small head sizes
who carry an AD-related gene, and further, 18 percent of the risk of AD has
been attributed solely to small head size
(less than 21.4 inches circumference;
Neurology, Oct 23, 2001).
Apoptosis, or programmed cell
death, has been observed in aging and
may even be a primary cause of the brain
cell death in AD (John Medina, PhD,
Geriatric Times, March 2002). Look at
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the background of cellular study in the
interesting science of cellular molecular
changes and their preprogrammed cycle
of generation and death. All human cells
are involved in an unstable genetic cellular environment consisting of a survival vs. death cycle (the ending cellular
death cycle, apoptosis, is cellular death).
Brain cell resilience and survival
through apoptotic pathways and nuclear
transcription factors can lead to improved cell survival. Will future medical science show that brain neurons and
cells regenerate? Recently, damaged
myocardial cells were proven to regenerate in cardiac transplanted patients.
Every cell is imbued with certain "terminator" complexes for its cell death
with a protein such as a member of the
capsase family being prominent. This
and the counter to the capsase protein
in the cell, cytosol (an apoptosis protein
inhibitor for lack of any other name),
are in continuing balance to ensure the
cell survival.
Cell death in the brain is prominent
in the concept of AD. Sustainment vs.
apoptosis of brain cells is a critical element of AD. As cellular apoptosis in the
brain occurs, slow but definable mental
deterioration follows.
Subtle at first, critical in the long run,
the eventual definition and psychological proving of AD progresses until total
AD occurs with its disastrous consequence.
In the 90's, an Italian study was done
to show the relationship of B amyloid
precursor protein to AD. The outcome
showed cytological apoptosis activated
by the B amyloidal precursor protein
and death of the brain neurons. Is this
test a consistent story of AD neuronal
death related to apoptosis or B amyloidal
interaction? The study is still ongoing
and is termed the Capsases Cascade
(Medina, John, Geriatric Times, Aug
2002).
The questions remain — what will
be the future relationship of neurofibrillary tangles, amyloidal plaques, and
apoptosis cellular changes? What will be
the future of cellular and genetic impact
in the process of neuronal change in AD

in the human brain? Can environmental, genetic, drug, social, or personal factors predict AD future diagnosis?
Are we destined to AD because of
apoptosis? Is apoptosis inevitable for all
of us and our cells? Is apoptosis programmed to end all cellular or human
life, and if so —why? Can apoptosis be
altered, changed, or prevented? Look at
the earliest human cells — why do they
mature, function, and then die off to
be replaced by a new fresh layer — only
to follow the plan of their predecessors?
Are all of the body's cellular elements
programmed to generate, function, live,
and die? And what about regeneration
— what "deviant" cell change in the
cycle leads eventually to a malignant
variant? What is the cellular genetic
regulatory mechanism that allows our
cells to rejuvenate, deform, or die or
change into "deviant" cells that are deleterious to life?
The field of electrotherapeutics began in the 1850's in the neurology studies of Duchenne. Today, neurotherapy
via pharmacology dominates. Newer stereotactic technique brain "pacemakers,"
using stimulation devices placed in the
brain, are being used to treat Parkinson
disease, seizures, obsessive compulsive
disorder, and movement disorders.
Could this also be an approach for AD?
Thus far, electrical device studies are not
encouraging, possibly due to the diffuse
nature of the disease.
In the last 15 years, we have learned
more about the causes of neurological
heredity disorders than in all the preceding centuries, back to the time of
Hippocrates. Will the emerging science
of genetics aid in the diagnosis and prevention of AD? (Fischbeck, KH, National Institute of Neurologic Disorders
and Stroke.)
AD, lipids, and vascular changes are
being studied more due to the pathophysiology of the disease. The E4 allele
for apolipoprotein has been shown to
be a risk factor for AD due to the vascular LDL-C receptor proteins. Higher
cholesterol plasma levels and sterols in
Continued on page 18
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For the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR)
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of hives, and size of hives, in patients with chronic idiopathic urticaria (CIU) 12 years of age and older
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Brief Summary (For full Prescribing Information, see package insert.)
INDICATIONS AND USAGE: Allergic Rhinitis: CLARINEX Tablets 5 mg are indicated for the relief of the nasal and non-nasal symptoms of allergic rhinitis (seasonal
and perennial) in patients 12 years of age and older.
Chronic Idiopathic Urticaria: CLARINEX Tablets are indicated for the symptomatic
relief of pruritus, reduction in the number of hives, and size of hives, in patients with
chronic idiopathic urticaria 12 years of age and older.
CONTRAINDICATIONS: CLARINEX Tablets 5 mg are contraindicated in patients
who are hypersensitive to this medication or to any of its ingredients, or to loratadine.
PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility: The carcinogenic potential of desloratadine was assessed using loratadine studies. In an
18-month study in mice and a 2-year study in rats, loratadine was administered in
the diet at doses up to 40 mg/kg/day in mice (estimated desloratadine and desloratadine metabolite exposures were approximately 3 times the AUC in humans at the
recommended daily oral dose) and 25 mg/kg/day in rats (estimated desloratadine
and desloratadine metabolite exposures were approximately 30 times the AUC in
humans at the recommended daily oral dose). Male mice given 40 mg/kg/day
loratadine had a significantly higher incidence of hepatocellular tumors (combined
adenomas and carcinomas) than concurrent controls. In rats, a significantly higher
incidence of hepatocellular tumors (combined adenomas and carcinomas) was
observed in males given 10 mg/kg/day and in majes and females given
25 mg/kg/day. The estimated desloratadine and desloratadine metabolite exposures
of rats given 10 mg/kg of loratadine were approximately 7 times the AUC in humans
at the recommended daily oral dose. The clinical significance of these findings during long-term use of desloratadine is not known.
In genotoxicity studies with desloratadine, there was no evidence of genotoxic
potential in a reverse mutation assay (Salmonella/E. co/i mammalian microsome
bacterial mutagenicity assay) or in two assays for chromosomal aberrations
(human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow
micronucleus assay).
There was no effect on female fertility in rats at desloratadine doses up to
24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 130 times the AUC in humans at the recommended daily oral dose). A
male specific decrease in fertility, demonstrated by reduced female conception rates,
decreased sperm numbers and motility, and histopathologic testicular changes,
occurred at an oral desloratadine dose of 12 mg/kg in rats (estimated desloratadine
exposures were approximately 45 times the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3
mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 8 times the AUC in humans at the recommended daily oral dose).
Pregnancy Category C: Desloratadine was not teratogenic in rats at doses up to
48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures
were approximately 210 times the AUC in humans at the recommended daily oral
dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures
were approximately 230 times the AUC in humans at the recommended daily oral
dose). In a separate study, an increase in pre-implantation loss and a decreased
number of implantations and fetuses were noted in female rats at 24 mg/kg (estimated desloratadine and desloratadine metabolite exposures were approximately
120 times the AUC in humans at the recommended daily oral dose). Reduced body
weight and slow righting reflex were reported in pups at doses of 9 mg/kg/day or
greater (estimated desloratadine and desloratadine metabolite exposures were
approximately 50 times or greater than the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on pup development at an oral dose of
3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 7 times the AUC in humans at the recommended daily oral dose).
There are, however, no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response,
desloratadine should be used during pregnancy only if clearly needed.
Nursing Mothers: Desloratadine passes into breast milk, therefore a decision
should be made whether to discontinue nursing or to discontinue desloratadine,
taking into account the importance of the drug to the mother.
Pediatric Use: The safety and effectiveness of CLARINEX Tablets in pediatric
patients under 12 years of age have not been established.
Geriatric Use: Clinical studies of desloratadine did not include sufficient numbers
of subjects aged 65 and over to determine whether they respond differently from
younger subjects. Other reported clinical experience has not identified differences
between the elderly and younger patients. In general, dose selection for an elderly
patient should be cautious, reflecting the greater frequency of decreased hepatic,
renal, or cardiac function, and of concomitant disease or other drug therapy, (see
CLINICAL PHARMACOLOGY - Special Populations).
Information for Patients: Patients should be instructed to use CLARINEX Tablets
as directed. As there are no food effects on bioavailability, patients can be instructed that CLARINEX Tablets may be taken without regard to meals. Patients should
be advised not to increase the dose or dosing frequency as studies have not demonstrated increased effectiveness at higher doses and somnolence may occur.

ADVERSE REACTIONS: Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2,834 patients received CLARINEX Tablets at doses of 2.5 mg to 20 mg daily,
of whom 1,655 patients received the recommended daily dose of 5 mg. In patients
receiving 5 mg daily, the rate of adverse events was similar between CLARINEX and
placebo-treated patients. The percent of patients who withdrew prematurely due to
adverse events was 2.4% in the CLARINEX group and 2.6% in the placebo group.
There were no serious adverse events in these trials in patients receiving desloratadine. All adverse events that were reported by greater than or equal to 2% of
patients who received the recommended daily dose of CLARINEX Tablets (5.0 mg
once-daily), and that were more common with CLARINEX Tablet than placebo, are
listed in Table 5.
Table 5
Incidence of Adverse Events Reported by > 2% of Allergic Rhinitis
Patients in Placebo-Controlled, Multiple-Dose Clinical Trials
CLARINEX Tablets 5 mg
Placebo
Adverse Experience
(n=1,655)
(n=1,652)
4.1%
Pharyngitis
2.0%
Dry Mouth
3.0%
1.9%
2.1%
Myalgia
1.8%
Fatigue
2.1%
1.2%
Somnolence
2.1%
1.8%
2.1%
Dysmenorrhea
1.6%
The frequency and magnitude of laboratory and electrocardiograph^ abnormalities were similar in CLARINEX and placebo-treated patients.
There were no differences in adverse events for subgroups of patients as defined
by gender, age, or race.
Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic
idiopathic urticaria, 211 patients received CLARINEX Tablets and 205 received
placebo. Adverse events that were reported by greater than or equal to 2% of
patients who received CLARINEX Tablets and that were more common with
CLARINEX than placebo were (rates for CLARINEX and placebo, respectively):
headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%),
pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).
The following spontaneous adverse events have been reported during the marketing of desloratadine: tachycardia, and rarely hypersensitiyity reactions (such as
rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), and elevated liver
enzymes including bilirubin.
DRUG ABUSE AND DEPENDENCE: There is no information to indicate that abuse
or dependency occurs with CLARINEX Tablets.
OVERDOSAGE: Information regarding acute overdosage is limited to experience
from clinical trials conducted during the development of the CLARINEX product. In
a dose ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.
Single daily doses of 45 mg were given to normal male and female volunteers for
10 days. All ECGs obtained in this study were manually read in a blinded fashion by
a cardiologist. In CLARINEX-treated subjects, there was an increase in mean heart
rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate
(QTC) by both the Bazett and Fridericia methods. Using the QTC (Bazett) there was a
mean increase of 8.1 msec in CLARINEX-treated subjects relative to placebo. Using
QTC (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated subjects relative to placebo. No clinically relevant adverse events were reported.
In the event of overdose, consider standard measures to remove any unabsorbed
drug. Symptomatic and supportive treatment is recommended. Desloratadine and
3-hydroxydesloratadine are not eliminated by hemodialysis.
Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the
AUC in humans at the recommended daily oral dose). The oral median lethal dose
in mice was 353 mg/kg (estimated desloratadine exposures were approximately
290 times the human daily oral dose on a mg/m2 basis). No deaths occurred at oral
doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were
approximately 810 times the human daily oral dose on a mg/m2 basis).
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COMPLEXITY AND SAFETY, PART n
Aviation is a very complex, highly distributed, highly dynamic domain similar to medicine. Both domains are
comprised of many diverse groups and individuals with agendas often in competition. Both domains involve
very real dangers for consumers.
BY CHARLES E. BILLINGS, MD, THE OHIO STATE UNIVERSITY, COLUMBUS, OHIO
Some Cautions
WANT TO suggest some tough
problems with which I think
you are going to have to deal in
the course of your searches for new
knowledge about system safety
problems. I have seen the emergence and growth of a substantial
number of voluntary reporting systems throughout the world during
the last 25 years, and sadly, the disappearance of some of them. I want
to conclude this with a few comments about the reasons some have
failed.
Relations with Regulatory Organizations: Our system is supported
by the Federal Aviation Administration, the regulatory and enforcement body for all of American civil
aviation. Yet the terms of our agreement give NASA full control over
the data and what is done with it.
We have made strenuous efforts to
keep our sponsor apprised of data
we are receiving, but it is naive to
expect that any government bureaucracy will ever be fully comfortable
with another, independent organization which has been specifically
designed to criticize its perceived
shortcomings in its own field of
expertise. About the best that can
be expected between the two agencies is some level of constructive
tension, and that only if deliberate
and continuous efforts are made to
maintain open channels of communication between them.

I

I don't know who may be tasked
to handle incident reporting in
medicine, but you can be assured
that the relationship between organizations that receive reports and
the agency or agencies that regulate
the domain from which they are
received will not always be a happy
one. We were unaware when we
began of the deep antipathy within
FAA staff concerning our establishment, and it has taken literally decades to begin to redress this problem. You would be well advised to
think hard about this when you
begin to design whatever mechanisms you plan to use to learn of
the operational problems that
threaten safety in your domain.
The Need for Consensus: We
were fortunate, in 1975, that virtually the entire aviation community recognized a need for better
data concerning operational problems. We briefed nearly everyone
we could find before formally presenting our ASRS proposal, and we
responded thoughtfully to community concerns and sensitivities in
the final design of the system. It
helped that civil aviation was a
fairly tidy domain whose ground
rules were understood by everybody, including ourselves (Designing such a system is not a task for
amateurs, however well-intended!).

The medical domain is immensely complex and less well ordered than was aviation when we
started. It is undergoing rapid and
dramatic change at this time, and
there is little agreement even about
its fundamental structure. I sense
no such unanimity of objectives
within medicine's community of
stakeholders, and the aims of some
elements of the community even
seem to be at direct variance with
those of other elements. Finally,
there is and will continue to be a
good deal of variability within the
body politic as to how health care
should be structured and managed.
All these factors will make the attainment of consensus about voluntary incident reporting far more
difficult than it was in aviation, and
yet I am convinced that without a
measure of agreement on the objectives of reporting mechanisms, their
realization will be very difficult.
The Need for Expertise and Objectivity: Where is organized medicine going to find a genuinely disinterested, objective, and knowledgeable organization that can be
trusted by the community to do this
job? And given the variety of skills
and knowledge its analysts will need
to have to make sense of the data,
how is the receiving organization
going to establish and maintain,
and pay, a core of dedicated experts
to be its analysts?
Continued
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Who will be its overseers? How
will the organization be insulated
from the political and social interests that will inevitably perceive a
threat in some of its findings and
interpretations? How will its data
be shielded from discovery with respect to identification of reporters
and identifying specifics of incidents that have been reported?
The Need for Resources: I hardly
need to mention that an organization to collect, analyze, learn from
and feed back to the community the
sorts of information for which you
are searching is not going to be
cheap. It will not be cheap in
money, or human or material resources to accomplish the tasks that
will be expected of it, nor will it be
cheap in terms of the time required
to make it work, then to determine
its usefulness and effectiveness.
If whomever is going to support
this effort is not prepared to invest
these resources for a period of several years, you should choose a
more limited set of expectations at
the outset, for the health care industry cannot really afford a major
safety information system failure,
given the high expectations of the
community and its elected representatives.
Can Incident Reporting Work in
Medicine? A final comment: I have
questioned whether an effective system for voluntary, confidential,
non-punitive reporting of medical
adverse events is achievable in our
present social and political climate.
In part, this is because I am pessimistic about reaching the level of
consensus that will be required
among the system's stakeholders,
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some of whose oxen run a high risk
of being gored by some of its findings. I have wondered for some time
whether a pilot study in a more orderly and structured environment,
such as that now being pursued by
the Veterans' Health Administration, would not be a lower-risk approach to the problem.
Yet, having said that, my experience as a physician tells me that
there are many operational problems that would benefit from a
well-designed, voluntary, confidential reporting and analysis system.
The Institute for Safe Medication
Practices, the Anesthesia Incident
Reporting program and others in
medicine, and our years of experience with ASRS, have convinced
me that useful new knowledge can
result from the thoughtful study of
data from medical practitioners, if
the people at the sharp end of the
health care system can be convinced
that it is in their best interests to
share what they know.
Woods and Cook (2000) have
said, "Virtually all the progress on
safety made thus far has been derived from individual reports or
small collections of cases that point
to vulnerabilities or 'genotypes' of
failure." The reporting system I
have described can give you access
to those reports. You will be surprised, and I hope u l t i m a t e l y
pleased, at how far they can go to
melt the "iceberg of ignorance."

FP
Prepared for the Premier CEO Leadership Forum, Aspen, Colorado, September 11, 1991.
© Charles E. Billings, MD, 2001

QUICKIES from page 3

• Diabetic neuropathy occurs progressively in patients both in absent
or tight control.
• In saphenous vein coronary
grafts, increased atherosclerotic
changes occur, felt secondary to reduced prostacyclin, nitric oxide,
and tissue plasminogen activator
levels in the donor vessel graft.
• Brain damage is correlated with
acceleration injuries.
—Parachute opening (7-30G)
—Aircraft dive recovery (4+G)
—Football helmet collision (231000G)
—Boxing head rotation (50100G)
—Helmeted race car collision
(200+G)
—Fall into fireman's net (20G)
—Rear end auto collision (515G)
• Rheumatoid arthritis is of unknown origin, progressive, and with
limited curative therapy.
• In rheumatoid arthritis, tumor
necrosis factor alpha stimulates
bone and joint destruction. TNFa
blockers are utilized in the anti-inflammatory therapy of rheumatoid
arthritis.
• Sociogenic illness, a new psychiatric term, is defined as fear, confusion, and life uncertainties resultant from bioterrorism.
• Popcorn factory workers exposed
to artificial seasoning or butter flavors can develop critical, irreversible lung disease. Does this concern
carry over to microwave popcorn
exposure?
• AIDS today has claimed more
lives than the 20-million-death flu
pandemic of 1918. Will AIDS
deaths exceed those of the MiddleAges plague, or smallpox, or syphilis, TB, or malaria?
FP
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NEW MEMBERS
CAMA WELCOMES THESE NEW MEMBERS TO OUR GROWING NETWORK OF AEROMEDICAL COLLEAGUES!

Mojgan Amirkham, MD
1100 North Tustin Ave., Suite F
Santa Ana, CA 93705-3509
Phone: 714-667-7922
Family Practice Pilot
AME

Liliana Cote, MD
Calle 43 N. 69080 2g
Bogota, Columbia
Phone: 0111-571-410-6168
Occupational Med.
AME

Lars Hertzog, MD
2977 Redondo Ave
Long Beach, CA 90806-2445
FAX: 562-595-6092
Ophthomology

AME

Michael Atta, MD
154 Conerstone Lane
Hot Springs, AR 71913-6560
Phone: 501-525-9675
Internal Med.

AME

Thomas J. Duncan, MD
2528 Cedar Park Loop S
Olypmia, WA 98501-6241
Phone: 360-754-6367
Family Practice

Albert F. Johary, MD
780 Aran Drive
Roswell.GA 30076-5129
Phone: 770-936-0900
Internal Med.
Pilot

AME

Julie M. Johnson, MD
3347 Deer Creek Trail
St. Cloud, MN 56301-8527
Family Practice Pilot

AME

AME

Gregory R. Dunnavant, MD
2124 S. 1640 W. #19
Woods Cross, UT 84087-2346
Phone: 801-580-3806
Emergency Med. Pilot
AME

Thomas E. Joiner, MD
1635 Raymond Rd.
Jackson, MS 39204-4204
Phone: 601-372-3998
Family Practice Pilot

AME

Neel Kanase, MD
1914 Apache Dr.
Dalhart, TX 79022-5246
Phone: 806-244-5668
Family Practice Pilot

AME

Thomas W. Kendall, MD
191 MontverdeDr.
Greenville, SC 29609-6651
Phone: 864-292-6000
Family Practice

AME

William W. Barrington, MD
200 Lothrop St., Suite B
Pittsburgh, PA 15213-2546
Phone: 412-647-6272
Cardiovascular
Pilot
George F. Bechara, MD
MEA Medical Department
Beirut Airport, PO Box 206
Beirut, Lebanon
Phone: 961-3-288620
Internal/Aviation Med.
Daniel Bejarano, MD
819 Washington Ave.
Dayton, OH 453201549
Aviation Med.

Joseph T. Farnese, MD
13 Fox Run
North Coldwell, NJ 07006-4173
Phone: 973-226-2835
Internal Med.
Pilot
AME
AME

AME

Barb Biehl
4918 97 Ave. CT
University Place, WA 98467-1121
Phone: 253-565-5057
Hector Brignoni, MD
P.O. Box 336610
Greeley, CO 80633-0611
Family Practice Pilot
Jonathan F. Busbee, MD
615 S. Center St.
Thomaston, GA 30286-4141
Phone: 706-647-2147
Internal Med.

AME

AME

AME

Hugh A. Coleman, DO
290 Clyde Morris Blvd.
Ormond Beach, FL 32174-5977
Phone: 386-615-9113
Family Practice
AME

Seth Feldman, DO
407 SE 24th St.
FT. Lauderdale, FL 33316-3915
Phone: 954-467-2140
Occupational Med.
AME
Leonard M. Fromer, MD
2825 Santa Monical Blvd.
Santa Monica, CA 90404-2429
Phone: 310-829-3130
Family Practice
AME
Robert Golub, MD
146-01 45th Ave.
Flushing, NY 11355-3915
Phone: 718-670-3135
Surgery
Pilot
Harold Haralson, MD
408 N. Main, P.O. Box 519
Noble, OK 73068-0519
Phone: 405-872-3885
Family Practice

Hashem Khorassani, MD
1 SOON. Dixie HWY
West Palm Beach,FL 33401-2716
Phone: 561-835-8787
Family Practice
AME
AME
Ronald Kirkwood, DO
2222 East Reata
Dear Park, TX 77536-4964
Phone: 281-479-1523
Family Practice Pilot

AME

AME
Gregory T. Lang, MD
1083 Crane Cove Blvd.
Gulf Breeze, FL 32563-3192
Phone: 850-934-5742
Aviation Med.
Pilot
AME
Continued —>
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Michael A. Layman, MD
403 W. Main St.
Belgrade, MT 59714-3401
Phone: 406-388-8708
Emergency Med.
Martin D. Louie, MD
P.O. Box 420955
San Diego, CA 92142-0955
Phone: 619-233-0100
Family Practice
Patrick M. Morgan, MD
7210 Broad River Rd.
Irmo, SC 29063
Phone: 803-781-9322
Family Practice Pilot
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Gregory S. Pepper, MD
4610 Sweetwater Blvd.
Sugar Land, TX 77479-3151
Phone: 281-265-8855
Cardiology
Pilot

AME

Roger H. Reed, MD
15444DedeauxRd.
Gulfport, MS 39503-2637
Phone: 228-832-9038
Family Practice

AME

Patricia L. Rehfield, DO
3960 Comanche Court
Grandville, MI 49418-1835
Phone: 616-534-4121
Family Practice
Pilot

AME

Michael J. Smith, MD
714 W. Hamilton Ave
Eau Claire, WI 54701-6937
Phone:715-830-9990
Internal Med.
Pilot

AME

Pat W. Spangler, DO
1534 Avellino Circle
Murfreesboro, TN 37130-7609
Phone: 615-898-2988
AME
Family Practice
Pilot

AME

Samuel E. Sprethe, MD
1206 Vaughn Rd
Burlington, NC 27217-2847
Phone: 336-226-0660
ENT

AME

AME

Sacha St. Hill, MD
11937USHWY271
Tyler, TX 75708-3154
Phone: 903-877-5919
Occupational Med.

AME

AME

John K. Stanton, DO
12004 Melody Drive
Westminster, CO 80234-4212
Phone: 303-452-9585
FamilyPractice

AME

AME

Arthur G. Wallace Jr., DO
717 S. Houston, Ste 407
Tulsa, OK 74127-9007
Phone: 918-584-0700
Emergency Med. Pilot

AME

Thomas R. Wolf, MD
5245 E. Knight Dr.
Tucson, AZ 85712-2147
Phone: 520-326-0115
Neurology
Pilot

AME

Jeffrey Muller, DO
1300 Union TWP, Suite 2
New Hyde Park, NY 11040-1759
Phone: 576-737-7202
Internal Med.
AME

Diane Rennirt, MD
5223 Shelbyville Rd.
Simpsonville, KY 40067-6515
Phone: 502-899-6955
Internal Med.

John J. Murray, MD
1240 North Ave.
Burlington, VT 05401-2713
Phone: 807-846-8100
Pediatrics

AMI',

Mark R. Rosenwasser, MD
37595 7 Mile
Livoria, MI 48152-1433
Phone: 734-996-1242
Family Practice

AME

J. Burr Ross, MD
9225 N. 3rd St.
Phoenix, AZ 85020-2439
Phone: 602-997-7263
Pulmonary
Pilot

AME

Leon G. Sheer, MD
23 Crossroads Dr.
Owings Mills, MD 21117-5420
Phone: 410-356-1575
Internal Med.
Pilot
AME

Alex L. Nguyen, MD
17319 Autumn Oak Way
Spring, TX 77379-5544
Phone: 281-453-7968
Internal Med.
Gino Ormeno, MD
SanBorjaSur 1014 DP4
Lima, 41 Peru
Phone: 511-225-6458
Aviation Med.

AME

Samuel K. Park, MD
4463 Birch St., Suite 100
Newport Beach, CA 92660-1912
Phone: 949-757-1150
Family Practice
AME
John R. Pedrotty, MD
1121 10th St.
Coronado, CA 92118-3401
Phone: 619-435-7100
Family Practice

AME

CALL FOR PAPERS
We are seeking your input for the next CAMA FlightPhysician. Needed is an interesting, challenging pilot certification case. Aviation Medical Examiners and CAMA physicians
have many pilot applicants. Are there occasions that develop
in your contact with these flyers that would be of interest to
your fellow examiners? Share your most memorable case short notes or long dissertations! We will give you full credit—
or anonymity, if that is your desire.
—Jim Almand
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Old A from page 8

alcohol consumption is associated with
a 42% reduced risk of dementia in individuals ages 55 or older."
Sixty years ago, there were no effective drugs for hypertension. Today there
are over 150. Also, until recently no
therapy was in use for AD. Today, three
AD drugs are of value, particularly when
used during AD's earliest stages. More
than 2,000 new patents for AD medicines are in trial worldwide today.
Currently, acetylcholinesterase inhibitors (ACIs) are used in AD, including:
• Donepezil (Aricept) — most commonly
used
• Rivastigmine (Exelon)
• Galantamine (Reminyl)
• Tacrine (Cognex) - first ACI, not used
today
ACIs help stabilize AD for 12-15
months, then renewed decline occurs. GI
side effects are most common. MMSE
testing is valuable in following usefulness
of ACIs and the progression of AD.
Other AD therapies:
• NSAIDS (Ibuprofen 400mg/day; N
England}Med, Nov2001) may reduce AD
likelihood by 30-60%
• Aspirin, also of value, but less so than
Ibuprofen
• Statins show up to 60% decrease in risk
of AD
• Estrogen — felt valuable related to endothelial effect
• Selegine - (NEngland]Med 1997) delayed progression of AD
• Vitamin E - 2000mg daily reported of
value
• Alternative medication (herbs). Use
with caution due to questionable effectiveness and side effects.
• Estrogen patches or oral hormone used
in women with mild to moderated AD can
improve memory and attention skills (Neurology, Aug 28, 2001). Also: Past or present
use of estrogen appears to protect against
cataracts.
• Miracle anti-aging cures are prominently displayed on the Internet. Entering
the term "anti-aging" on one search engine
turned up 160,000 leads in 0.45 seconds.
The US Senate Aging Committee estimated that $27 billion was spent on "health
supplements" in 2001, and most of the

the brain may increase B-amyloid production and E4 apolipoprotein concentration and result in brain cell dendritic
plaques found in AD.
This lipid dependent process is felt to
be associated with the lower risk of AD
found in patients treated for CV disease
with statins (Engelhart MJ et al. Dietary
intake of antioxidants and risk of
Alzheimer
disease.
JAMA
2002;287:3223-9).
Additionally, new reports suggest a
doubling of AD risk in patients with high
plasma homocysteine levels. This finding was independent of other risk factors (APO-E genotype and family history). AD therapeutic trials are underway to test if dietary measures that lower
homocysteine levels will reduce AD risk.
High doses of folate and B vitamins are
also being studied to slow the rate of cognitive decline in patients with AD (TV
England] Med 346 [7] 2002).
"Statins are the new aspirin. If 10
million high-risk people worldwide were
to go on statin treatment, 50,000 lives
would be saved yearly" (Collins, R., Oxford University UK). A recent study reports that patients taking statins were
70% less likely to develop dementia than
patients untreated for hyperlipidemia
were. Statins reduce production of Bamyloid and E4 apolipoprotein associated with the formation of dendritic
plaques of AD. Other non-statin lipid
lowering drugs (such as fibrates,
cholestyramine, or nicotinic acid) did not
offer similar protection (Neurology, Sept
25,2001).
Basic cognitive testing may be of value
in patients for measuring and improving
visual and performance driving ability
and lead to earlier AD diagnosis. There
are six billion people in the world; thirtyfive million are on the Internet. Will the
Internet eventually replace the proven
remedy of AD, the crossword puzzle?
Reducing TV time and increasing activity slows AD progression and benefits the
patient (Brangman, S, MD, SUNY).
Another study from England (Lancet, Jan
26 2002) found that "light to moderate

August 2003
consumers were older citizens (Geriatric
Times, March 2002). Many of these "alternative medication" supplements, commonly available, have serious adverse affects
and questionable value.
Emphasizing the dubious value of
these supplements a JAMA March 27,
2002, report, PI 518, cited a panel of the
"International Longevity Center, USA,"
who stated the "anti-aging movement
belongs to a long chain of quacks, snakeoil salesmen, and charlatans,+62" and
that there is no evidence that medicine
can yet slow aging in people, mice, or rats!
The panel did cite encouraging progress
in therapies such as diet, genetic or chromosomal manipulation, antioxidants,
and stem cells.
When will the diagnosis, prevention,
and pretreatment of senility, Alzheimer's,
dementia, and mania be possible? Although these disorders are similar and
often interrelated, cognitive impairment
is consistently present, and therein lies a
reason why similar drug therapy can be
useful in patients with mixtures of any
of the above.
Significant challenges yet exist in the
diagnosis, management, therapy, and future protection against AD. Aside from
government and research endeavors, the
Alzheimer's Association remains the bedrock of support for families involved in
this progressive brain deterioration process. The marked public and family impact of this disease will escalate as our
population ages. Current therapeutic approaches toward abetting AD have led to
limited success. Research must
proactively continue to pursue a source
for controlling the onset of brain changes.
Today's retroactive therapies are poorly
effective.
Certainly, most of the many current
approaches to diagnosis and prevention
of AD are encouraging. Many of today's
most promising researchers lend hope to
the eventual resolution of a uniform direction to medicine's present quandary
of AD. Reassure your patients! There
surely will be a better story tomorrow!
FP
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SEATTLE from page 1
Mediterranean, and Egyptian arts.
After the tour, we take a journey to
Sky City, the world-famous revolving restaurant, where we will be
served the finest in Pacific Northwest
cuisine. You will have the opportunity to soar a little higher to the Obwho need help will be provided cart
servation Deck, 520 feet above
transportation.
ground, where you will discover
And on Saturday morning, last but
breathtaking indoor and outdoor
not least, a tour of the Museum of
viewing.
Flight. The museum features the hisOn Friday morning, we will be
tory of aviation technology. Exhibits
transported to Everett, Washington,
in the restored Red Barn, Boeing's
to see the largest building in the world
first manufacturing plant, document
during a special tour of the Boeing
flight from the 13th century through
plant, which includes a presentation
the late 1930s. The Great Gallery
and visit to the assembly line where
complex contains more than 50 airthe 747 - 767 - 777 aircraft are as-craft, more than 20 of which are sussembled. Our hosts ask that we dress
pended from the ceiling. Among
appropriately for the tour— dresses
those exhibited are a DC-3, a superare not permitted, along with high
sonic M/D-21 Blackbird and drone,
heels or opened-toed shoes. Also,
a restored World War II Corsair, a
children under 12 are not permitted
1929 Boeing Model 80A-1, a 1926
on the tour, no cameras or recorders
Swallow, an Apollo command modare permitted, and you must be preule, and the first presidential jet.
pared to do a lot of walking. Those
There also is a simulated air traffic

control tower. The "Rendezvous in
Space" exhibit documents American's
manned space program and the life
of astronaut Charles "Pete" Conrad.
The Hangar is a hands-on exhibit
area where children (and others) can
work with equipment and learn a
variety of skills involving designing,
building, maintaining, and flying aircraft. On Boeing Field, is a World
War II-era B-29. "The Dream" is an
8-minute film presentation focusing on the fulfillment of man's desire to fly.
Do not miss this opportunity to
attend a wonderful meeting and enjoy the great Northwest. A large turnout is expected, so get your reservations in soon. You may FAX your reservation to CAMA Headquarters:
(405) 848-1053
or call
(405) 840-0199
CAMA President Robin Dodge,
M.D., along with the Officers and
Board Members, looks forward to
seeing you in Seattle.

FP

CAM A CONSULTANTS
To our new members and as a reminder to all: This is a list of more experienced AMEs that have volunteered to help with
troublesome certification cases. For involved questions, E-mail or fax is preferred. This list is NOT for use by airmen, but
solely for AMEs within the CAMA membership.
Frank H. Austin, MD
Phone:703-471-1769
Fax: 703-450-3104
E-mail: FHAustin@aol.com

EST

A. J. Parmet, MD
CST
Phone: 816-561-3480
Fax: 816-561-4043
E-mail: AJParmet@cysource.com

Charles A. Berry, MD
Phone: 713-978-7755
Fax: 713-978-5001
E-mail: docchuckb@aol.com

CST

Gordon L. Hitter, DO
Phone: 520-776-9830
Fax: 513-751-5660
E-mail: gordon@rittaire.com

MST

A. Duane Catterson, MD
CST
Phone: 281-873-0111
Fax: 281-873-0660
E-mail: cattersib@worldnet.att.net

Robert A. Stein, MD
Phone: 513-751-0080
Fax: 513-751-5660
E-mail: Bobxtein47@aol.com

EST

Marc C. Eidson, MD
CST
Phone: 817-599-9472
Fax: 817- 599-9472
E-mail: MARK@EIDSON.ORG

M. Young Stokes III, MD
Phone 903-465-6707
Fax: 903-465-6744
E-mail: mysiii@flash.net

CST

James L. Tucker, MD
EST
Phone: 256-329-7788
E-mail: JLTucker@mindspring.com
Mark Thoman, MD
Phone: 515-244-4229
Fax: 515-244-1131
E-mail: PARO1795@aol.com

CST

John D. Hastings, MD
Phone: 918-747-7517
Fax: 918-742-7947
E-mail: hastings20@msn.com

CST

H. Stacy Vereen, MD
Phone: 404-761-2166
Fax: 404-761-2168
E-mail: Stacyv@earthlink.net

EST

n The Horizon
FAA AVIATION MEDICAL EXAMINER
SEMINAR SCHEDULE
2003
September 15-19 _ Oklahoma City, Okla. (Basic)
October 3 - 5

Salt Lake City, Utah (Ophth/Otolaryn/
Endocrin)

November 3 - 7

Oklahoma City, Okla. (Basic)

2004 BASIC SEMINARS
March 15-19

Oklahoma City, Okla.

June 21-25

Oklahoma City, Okla.

September 13-17

Oklahoma City, Okla.

November 15-19

Oklahoma City, Okla.

For information, call your regional flight surgeon. To
schedule a seminar, call the FAA Civil Aerospace Medical
Institute AME Programs Office ( 405) 954-4830

AEROSPACE MEDICAL
ASSOCIATION'S ANNUAL MEETING
SCHEDULE
May 2-6, 2004

Anchorage, Alaska

May 8-12, 2005

Kansas City, Missouri

CIVIL AVIATION MEDICAL
ASSOCIATION'S ANNUAL MEETING
SCHEDULE
October 8-12, 2003 _ Seattle, Washington,
Marriott Sea Tac Hotel
October 6-10, 2004 _ Omaha, Nebraska,
Marriott Omaha Hotel
October 5 - 9 , 2005
Charleston, South
Carolina, TBA
October 4 - 8, 2006
Ottawa, Canada,
Ottawa Marriott Hotel
SEATTLE SIGHTS
Boeing 777
assembly
hangar

CAMA Headquarters
P.O. Box 23864
Oklahoma City, OK 73123-2864

Boeing 777

Science Center

Space Toys

Museum of Flight

